Harbour BioMed
02142
Performance
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibody therapeutics, particularly in oncology and immunology. The company utilizes proprietary technology platforms, such as Harbour Mice®, to generate fully human monoclonal antibodies and advanced immune cell engagers (HBICE®). Harbour BioMed enhances its R&D capabilities through collaborations and strategic acquisitions to build a robust pipeline of therapeutic antibodies.
Recent News
The US FDA Grants IND Clearance to Harbour BioMed’s HBM7004 to Initiate P-I Trial in Advanced Solid Tumors
Harbour BioMed Gains FDA Clearance for First-in-Human Study of B7H4xCD3 Bispecific Antibody HBM7004
China Investors Energise Hong Kong Biotech Stocks. Is Foreign Money Missing Out?
Windward Bio Doses First Patients in Phase II SIRIUS COPD Trial
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
Harbour Posts Preclinical Data on Would-Be Rival to Eli Lilly’s $1.9B Obesity Bet
Windward Bio Secures $165 Million to Accelerate Late‑Stage Asthma and COPD Trials